Michael  Geffner net worth and biography

Michael Geffner Biography and Net Worth

Chief Medical Officer of Immunovant

Prior to joining Immunovant, Dr. Geffner was the Chief Medical Officer and head of Product Development for BlueSphere Bio (BSB), an Immuno-Oncology company focused on developing adoptive T-cell therapeutics. Before his role at BSB, he led Hematology Clinical Development for the danicopan development program and was the Head of Global Medical Affairs for Achillion Pharmaceuticals (now Astra Zeneca). Prior to Achillion, he spent 15 years in various senior leadership positions at Schering-Plough/Merck across Clinical Development, Clinical Operations, and Medical Affairs. His other prior roles include, Head of the Anti-infectives/hospital and specialty care Medical Affairs teams, US Medical Affairs integration lead, and Clinical Development Leader.

Dr. Geffner has dual board certification from the American Board of Pediatrics and The American Board of Psychiatry and Neurology, with special competency in Child Neurology. He is a Graduate of Albany Medical College and holds an MBA from Fairleigh Dickinson University

What is Michael Geffner's net worth?

The estimated net worth of Michael Geffner is at least $2.69 million as of January 22nd, 2025. Dr. Geffner owns 132,314 shares of Immunovant stock worth more than $2,689,944 as of February 15th. This net worth estimate does not reflect any other investments that Dr. Geffner may own. Learn More about Michael Geffner's net worth.

How do I contact Michael Geffner?

The corporate mailing address for Dr. Geffner and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at info@immunovant.com. Learn More on Michael Geffner's contact information.

Has Michael Geffner been buying or selling shares of Immunovant?

Over the course of the past ninety days, Michael Geffner has sold $62,678.63 in shares of Immunovant stock. Most recently, Michael Geffner sold 2,657 shares of the business's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $23.59, for a transaction totalling $62,678.63. Following the completion of the sale, the insider now directly owns 132,314 shares of the company's stock, valued at $3,121,287.26. Learn More on Michael Geffner's trading history.

Who are Immunovant's active insiders?

Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.

Are insiders buying or selling shares of Immunovant?

During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,845,010 shares worth more than $336,900,200.00. During the last twelve months, insiders at the sold shares 40 times. They sold a total of 241,656 shares worth more than $6,778,366.96. The most recent insider tranaction occured on January, 22nd when CTO Jay S Stout sold 2,195 shares worth more than $51,780.05. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.

Information on this page was last updated on 1/22/2025.

Michael Geffner Insider Trading History at Immunovant

See Full Table

Michael Geffner Buying and Selling Activity at Immunovant

This chart shows Michael Geffner's buying and selling at Immunovant by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$63ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Immunovant Company Overview

Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $20.33
Low: $19.89
High: $20.49

50 Day Range

MA: $23.87
Low: $19.22
High: $28.94

2 Week Range

Now: $20.33
Low: $19.07
High: $39.55

Volume

1,241,001 shs

Average Volume

1,356,782 shs

Market Capitalization

$3.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65